Asset Details
Do you wish to reserve the book?
Efficacy of Procox® Oral Suspension for Dogs (0.1% Emodepside and 2% Toltrazuril) against Experimental Nematode (Toxocara cati and Ancylostoma tubaeforme) Infections in Cats
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy of Procox® Oral Suspension for Dogs (0.1% Emodepside and 2% Toltrazuril) against Experimental Nematode (Toxocara cati and Ancylostoma tubaeforme) Infections in Cats
Do you wish to request the book?
Efficacy of Procox® Oral Suspension for Dogs (0.1% Emodepside and 2% Toltrazuril) against Experimental Nematode (Toxocara cati and Ancylostoma tubaeforme) Infections in Cats
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy of Procox® Oral Suspension for Dogs (0.1% Emodepside and 2% Toltrazuril) against Experimental Nematode (Toxocara cati and Ancylostoma tubaeforme) Infections in Cats
2011
Overview
Two exploratory studies were performed to determine the optimum therapeutic dose of Procox® for the removal of experimental infection with mature adult Toxocara (T.) cati and Ancylostoma (A.) tubaeforme in kittens. Procox® is a new oral suspension containing a combination of the nematocidal and coccidiocidal active principles emodepside (0.1 %) and toltrazuril (2 %).In the first study, 18 eight-weeks-old kittens were inoculated with 450 L3 larvae of T. cati. 56 days after infection, the kittens were allocated to three treatment groups and were treated with 0.5 mg emodepside/kg body weight (group 1), 0.25 mg emodepside/kg body weight (group 2) and 0.1 mg emodepside/kg body weight (group 3), respectively. In the second study, 10 eight-weeks-old kittens were inoculated with 350 L3 larvae of A. tubaeforme. Four weeks after infection, the kittens were allocated to two treatment groups and were treated with 0.1 mg emodepside/kg body weight (group 1) or 0.25 mg emodepside/kg body weight (group 2). In both studies, all kittens received a reference treatment with Drontal® (230 mg pyrantel embonate and 20 mg praziquantel per tablet) at the recommended dose of one tablet/4 kg body weight 5 days after treatment with Procox®. Anthelmintic efficacy was calculated by reduction in worm numbers expelled with the faeces following treatment with Procox® as compared with faecal worm numbers after reference treatment with Drontal®, by thus avoiding necropsy of the animals.In the T. cati study, emodepside was at 99.9 %, 100 % and 96.5 % effective at a dosage of 0.5 mg, 0.25 mg and 0.1 mg per kg body weight, respectively. Against A. tubaeforme emodepside was at 95.7 % and 100 % effective at a dosage of 0.1 mg and 0.25 mg per kg body weight. No adverse events were seen during either study.It can be concluded that Procox® is efficacious for the control of mature adult T. cati and A. tubaeforme infections in cats at a single-dose rate of 0.25 mg emodepside/kg body weight.
Publisher
Springer Nature B.V
Subject
